Tamayo J A, Peña J C
Departamento de Nefrología y Metabolismo Mineral, Instituto Nacional de la Nutrición Salvador Zubirán.
Gac Med Mex. 1990 Nov-Dec;126(6):497-505; discussion 505-7.
Kidney and urinary stone disease is a major public health problem which requires a systemic clinical and biochemical evaluation to establish a precise diagnosis and well oriented therapy. This study reviews the results of a protocol designed to establish the metabolic abnormalities that occurred in 626 consecutive renal stone patients studied in two periods; group I (1979-1987) 441 cases and group II (1987-1989) 185 cases. The group I included the following determinations before and after a five day oral calcium load: serum and 24 hr urine electrolytes, divalent cations, phosphate, uric acid, cystine, glomerular filtration rate, parathyroid function evaluation with PTH and Tm Phosphate and since 1982 also (Ia) cAMP. In group II we also determined inhibitors of crystallization (magnesium and citrate) and promoters of nucleation (oxalate). In 185 cases of group I, we monitored months of follow up after metabolic evaluation and the number of stones formed per patient/year before and after treatment was begun. In group I we detected some variety of metabolic abnormality in 88.2 percent of our patients and in group II increased to 96.2 percent. A two year follow up was recorded in 55 percent and four year follow up in 39 percent of our cases. The stone/patient/year formation rate before treatment was 2.8 and significantly decreased to 0.8 after treatment. The highly diagnostic efficiency, the long term follow up and the adequacy of treatment significantly decreased stone activity in this group of patients. We concluded that this protocol should be included in the systematic evaluation of kidney stone patients.
肾和尿路结石病是一个重大的公共卫生问题,需要进行系统的临床和生化评估,以确立准确的诊断和合理的治疗方案。本研究回顾了一项方案的结果,该方案旨在确定在两个阶段研究的626例连续性肾结石患者中发生的代谢异常情况;第一组(1979 - 1987年)441例,第二组(1987 - 1989年)185例。第一组在为期五天的口服钙负荷前后进行了以下测定:血清和24小时尿电解质、二价阳离子、磷酸盐、尿酸、胱氨酸、肾小球滤过率、用甲状旁腺激素(PTH)和Tm磷酸盐评估甲状旁腺功能,自1982年起还测定了(Ia)环磷酸腺苷(cAMP)。在第二组中,我们还测定了结晶抑制剂(镁和柠檬酸盐)和成核促进剂(草酸盐)。在第一组的185例患者中,我们在代谢评估后的几个月进行了随访,并记录了治疗开始前后每位患者每年形成的结石数量。在第一组中,我们在88.2%的患者中检测到了多种代谢异常,在第二组中这一比例增至96.2%。我们对55%的病例进行了两年的随访,对39%的病例进行了四年的随访。治疗前每位患者每年的结石形成率为2.8,治疗后显著降至0.8。该方案具有高度的诊断效率、长期随访以及充分的治疗,显著降低了该组患者的结石活动度。我们得出结论,该方案应纳入肾结石患者的系统评估中。